The need for a national infrastructure to improve the rational use of therapeutics

Pharmacoepidemiology and Drug Safety

Volumn 11, Issue 4, 2002, Pages 319-327

  Califf, Robert M ^a,b  

^a Centers for Education and Research on Therapeutics   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Agency for healthcare research and quality; Biologics; Cisapride; Clinical pharmacology; Food and drug administration; Institute of medicine; Medical devices; Prescription drugs; Rotavirus vaccine; Troglitazone

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; NEUROLEPTIC AGENT; RAMIPRIL; ROTAVIRUS VACCINE; TERFENADINE; TROGLITAZONE;

ARTICLE; CLINICAL PRACTICE; CONSUMER; DRUG SAFETY; DRUG UTILIZATION; EXPECTATION; GENERAL PRACTITIONER; GOVERNMENT; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; ISCHEMIC HEART DISEASE; LIVER TOXICITY; LONG QT SYNDROME; MEDICAL CARE; MEDICAL EDUCATION; MEDICAL RESEARCH; PATIENT CARE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RISK MANAGEMENT; SCHIZOPHRENIA; SUDDEN DEATH; TORSADE DES POINTES; DRUG THERAPY; FOOD AND DRUG ADMINISTRATION; ORGANIZATION; PUBLIC RELATIONS; UNITED STATES;

DRUG THERAPY; HEALTH POLICY; HUMAN; INSTITUTE OF MEDICINE (U.S.); INTERINSTITUTIONAL RELATIONS; QUALITY OF HEALTH CARE; SUPPORT, U.S. GOV'T, P.H.S.; UNITED STATES; UNITED STATES AGENCY FOR HEALTHCARE RESEARCH AND QUALITY; UNITED STATES FOOD AND DRUG ADMINISTRATION; HUMANS;

EID: 0035986736     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.699     Document Type: Article

References (51)

1. To Err is Human: Building a Safer Health System
2. Crossing the Quality Chasm: A New Health System for the 21st Century
3. The safety of newly approved medicines: Do recent market removals mean there is a problem?
4. From the Food and Drug Administration: Withdrawal of troglitazone and cisapride
5. Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to the United States Food and Drug Administration
6. Contraindicated use of cisapride: The impact of an FDA regulatory action
7. Intussusception among recipients of rotavirus vaccine-United States, 1998-1999
8. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients
9. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
10. A comparison of outcomes in men 11 years after heart-valve replacement with a mechanical valve or bioprosthesis
11. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction
12. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines-report of the National Multicenter Trial
13. Lack of an apparent association between intussusception and wild or vaccine rotavirus infection
14. Good news for experimental concept but bad news for clinically effective therapy
15. Aspirin use is low among United States outpatients with coronary artery disease
16. Underuse of aspirin in a referral population with documented coronary artery disease
17. Treatment with beta-adrenergic blocking agents after myocardial infarction: From randomized trials to clinical practice
18. Reasons for underuse of angiotensin converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction
19. The underrecognition and undertreatment of depression: What is the breadth and depth of the problem?
20. Usefulness of inhospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality
21. Compliance with and dosing of angiotensin-converting-enzyme inhibitors before and after hospitalization
22. Drug interactions with St. John's wort
23. Adverse events with ephedra and other botanical dietary supplements
24. Assessment and reporting of clinical pharmacology information in drug labeling
25. Cognition experiments: Optimizing patient comprehension through medicine information leaflets
26. Drug labeling revisions-guaranteed to fail?
27. The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost
28. Insurance and new technology: From hospital to drugstore
29. The price of progress: Prescription drugs in the health care market
30. The pause that refeshes, or does it? Mechanisms in torsades de pointes
31. Thiazolidinedoines and liver toxicity
32. Clinical pharmacology studies in patients with renal impairment: Past experience and regulatory perspectives
33. Will genetics revolutionize medicine?
34. Pharmacogenetics and drug-induced arrhythmias
35. Contraindicated use of cisapride: Impact of Food and Drug Administration regulatory action
36. How do observational studies expand the evidence base for therapy?
37. Improving clinical decisions and outcomes with information: A review
38. Potentially inappropriate medication use in the community-dwelling elderly: Findings from the 1996 Medical Expenditure Panel Survey
39. Guided medication dosing for inpatients with renal insufficiency
40. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin
41. Registry for torsades de pointes with drug treatment exists
42. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
43. Antipsychotics and the risk of sudden death
44. Risk management of marketed drugs: FDA and the interface with the practice of medicine
45. Formal education about medication errors in internal medicine clerkships
46. Educational program for physicians to reduce use of non-steroidal anti-inflammatory drugs among community-dwelling elderly persons: A randomized controlled trial
47. Nutritional rickets in African-American breast-fed infants